GRCL - Gracell gains as FDA clears another study for lead asset
2023-11-27 13:29:09 ET
More on Gracell Biotechnologies
- Gracell Biotechnologies Inc. (GRCL) Q3 2023 Earnings Call Transcript
- Gracell Biotechnologies: A CAR-T Company Flying Under Your Radar
- Gracell Biotechnologies Q3 GAAP EPS of -$0.51 misses by $0.38
- Gracell draws Buy at Stifel on upcoming readout for lead asset
- Seeking Alpha’s Quant Rating on Gracell Biotechnologies
For further details see:
Gracell gains as FDA clears another study for lead asset